AspirinAnti-Inflammatory Agents, Non-SteroidalCyclooxygenase InhibitorsCyclooxygenase 2 InhibitorsIbuprofenPlatelet Aggregation InhibitorsNaproxenDiclofenacProstaglandin-Endoperoxide SynthasesCyclooxygenase 1Cyclooxygenase 2AcetaminophenGastrointestinal DiseasesIndomethacinThromboxane B2KetoprofenSalicylatesSulfonamidesGastrointestinal HemorrhageTiclopidineSulindacPyrazolesPiroxicamSulfonesStomach UlcerEtodolacLactonesAnalgesics, Non-NarcoticPlatelet AggregationDrug Therapy, CombinationThiazinesNitrobenzenesPlatelet Function TestsPeptic UlcerGastric MucosaSodium SalicylateRisk FactorsPeptic Ulcer HemorrhageAsthma, Aspirin-InducedBlood PlateletsDinoprostoneDose-Response Relationship, DrugDrug InteractionsProstaglandinsOsteoarthritisTablets, Enteric-CoatedIsoenzymesDrug HypersensitivitySafety-Based Drug WithdrawalsAnticoagulantsDouble-Blind MethodFibrinolytic AgentsWarfarinTreatment OutcomeHemorrhageProspective StudiesAnti-Ulcer AgentsArthritisChemopreventionRandomized Controlled Trials as TopicBleeding TimeKetorolacAnticarcinogenic AgentsMisoprostolThrombosisPlatelet ActivationProton Pump InhibitorsThromboxanesTime FactorsCase-Control StudiesThromboxane A2Membrane ProteinsAnalgesicsSalicylic AcidMyocardial InfarctionRisk AssessmentProstaglandin AntagonistsColorectal NeoplasmsDuodenal UlcerPainStomach DiseasesDipyridamoleCardiovascular DiseasesDrug PrescriptionsDrug UtilizationCohort StudiesLipoxinsDrug Administration ScheduleEpoprostenolDrug ResistanceStrokeArachidonic AcidRiskIncidenceSulfinpyrazoneAdministration, OralFollow-Up StudiesAnti-Inflammatory AgentsReye SyndromeOdds Ratio